EpimAb Biotherapeutics

EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.

Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule. As a novel drug class, bi-specifics provide additional options for the treatment of many life-threatening diseases such as cancer. However, even minor modifications to any pharmaceutically active biologic such as an antibody can significantly change the properties critical to its development, such as its binding properties, the pharmacokinetics, its stability, solubility and the ability to produce it in sufficient quantities at reasonable costs. This challenge has prevented a majority of bi-specific antibodies of potential interest to scientists and clinicians from advancing into clinical development because their drug-like features were compromised. Thus, the need for a new generation of bi-specific antibody therapeutics in the pharmaceutical industry remains high.

EpimAb Biotherapeutics headquartered in Asia, operates in the Biotechnology, Health Care, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $10.5B in funding across 48 round(s). With a team of 11-50 employees, EpimAb Biotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - EpimAb Biotherapeutics, raised $25.0M. Discover more about their projects, partnerships, and impact on our platform.